文献速递神经免疫

儿童肥胖与多发性硬化风险及一线疾病修饰药物反应的相关性

Association of Obesity With Multiple Sclerosis Risk and Response to First-line Disease Modifying Drugs in Children.
PubMed 文献 · JAMA Neurol · 2019-01-01

该单中心回顾性研究纳入453例复发缓解型儿童多发性硬化患者,比较不同BMI分层与疾病风险及一线干扰素β和醋酸格拉替雷治疗反应的关系。结果发现肥胖与男女童MS风险约两倍升高相关,且肥胖患者一线治疗期间年复发率更高、更常升级二线治疗,基线影像与残疾进展与BMI无关。

要点

  • 肥胖使男女童MS风险约升高两倍(女孩OR 2.19,男孩OR 2.14)。
  • 肥胖患儿一线干扰素β或醋酸格拉替雷治疗年复发率更高(1.29 vs 0.72)。
  • 肥胖患儿更常需二线治疗,基线影像与EDSS进展与BMI无关。

核心结论

  • 儿童MS风险升高与肥胖相关,肥胖患者对一线药物反应不佳。
  • 药代动力学改变可能是治疗反应差异的主要因素。
  • 达到健康体重或按BMI调整剂量可能改善治疗反应。

研究设计与样本

  • 单中心回顾性研究,使用德国哥廷根儿童与青少年MS中心病历及数据库。
  • 纳入453例复发缓解型儿童MS且诊断6个月内测量BMI的患者,平均病程38.4个月。

主要发现

  • 诊断时126例(27.8%)超重或肥胖;肥胖与男女童MS风险约两倍升高相关(女孩OR 2.19,95%CI 1.5-3.1,P<.001;男孩OR 2.14,95%CI 1.3-3.5,P=.003)。
  • 肥胖患者一线干扰素β和醋酸格拉替雷治疗期间年复发率显著更高(1.29 vs 0.72,P<.001)。
  • 肥胖患者二线治疗比例更高(21/37[56.8%] vs 48/124[38.7%],P=.06)。
  • 基线神经影像、首次至第二次发作间隔、治疗前复发及EDSS进展与BMI无相关性。

关键数值与推荐

  • BMI分层:非超重≤90百分位,超重>90-97百分位,肥胖>97百分位。
  • 肥胖与MS风险:女孩OR 2.19(95%CI 1.5-3.1,P<.001),男孩OR 2.14(95%CI 1.3-3.5,P=.003)。
  • 一线治疗年复发率:肥胖1.29 vs 非超重0.72(P<.001)。
  • 二线治疗比例:肥胖56.8%(21/37) vs 非超重38.7%(48/124),P=.06。

临床怎么用

  • 对儿童MS患者应评估BMI,肥胖者需关注一线干扰素β或醋酸格拉替雷反应可能不佳。
  • 肥胖患儿治疗反应差时可考虑尽早评估二线治疗或按BMI调整剂量。
  • 促进健康体重可能作为改善儿童MS治疗反应的辅助策略。

局限性

  • 单中心回顾性设计,样本来自单一德国中心。
  • 二线治疗比例差异未达传统统计学显著(P=.06)。
  • 药代动力学改变为推测因素,原文未直接验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Obesity reportedly increases the risk of pediatric multiple sclerosis (MS), but little is known about its association with disease course. OBJECTIVE: To investigate the association of obesity with pediatric MS risk and with first-line therapy response among children with MS. DESIGN, SETTING, AND PARTICIPANTS: This single-center retrospective study used the medical records and database at the Center for MS in Childhood and Adolescence, Göttingen, Germany. The study included 453 patients with relapsing-remitting pediatric MS and body mass index (BMI) measurement taken within 6 months of diagnosis. Onset of the disease occurred between April 28, 1990, and June 26, 2016, and the mean disease duration was 38.4 months. Data were collected from July 14, 2016, to December 18, 2017. MAIN OUTCOMES AND MEASURES: Data on BMIs were stratified by sex and age using German BMI references and compared with the BMI data of 14 747 controls from a nationwide child health survey for odds ratio (OR) estimates. Baseline magnetic resonance imaging findings, intervals between first and second MS attacks, annualized relapse rates before and during treatment with interferon beta-1a or -1b and glatiramer acetate, frequency of second-line treatment, and Expanded Disability Status Scale (EDSS) scores were compared between nonoverweight (BMI≤90th percentile), overweight (BMI>90th-97th percentile), and obese (BMI>97th percentile) patients. RESULTS: In total, 453 patients with pediatric MS were included, of whom 306 (67.5%) were female, and the mean (SD) age at diagnosis was 13.7 (2.7) years. At diagnosis, 126 patients (27.8%) were overweight or obese, with obesity associated with statistically significant twofold odds of MS in both sexes (girls OR, 2.19; 95% CI, 1.5-3.1; P < .001 vs boys OR, 2.14; 95% CI, 1.3-3.5; P = .003). Obese patients, compared with nonoverweight patients, had statistically significantly more relapses on first-line treatment with interferon beta and glatiramer acetate (ARR, 1.29 vs 0.72; P < .001) and a higher rate of second-line treatment (21 [56.8%] of 37 vs 48 [38.7%] of 124; P = .06). Baseline neuroimaging, interval between first and second MS attacks, pretreatment relapses, and EDSS progression scores were not correlated with BMI. CONCLUSIONS AND RELEVANCE: In this study, increased pediatric MS risk appeared to be associated with obesity, and obese patients did not respond well to first-line medications; altered pharmacokinetics appeared to be most likely factors in treatment response, suggesting that achieving healthy weight or adjusting the dose according to BMI could improve therapy response.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Huppke B, Ellenberger D, Hummel H, et al. Association of Obesity With Multiple Sclerosis Risk and Response to First-line Disease Modifying Drugs in Children. JAMA Neurol. 2019. PMID: 31305922. doi:10.1001/jamaneurol.2019.1997

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。